Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
DC Rooftop Mounted Vehicle Air Conditioners
Contact Us● Strong air volume, fast cooling
● Lightweight design, intelligent design
● Longer battery life, meeting the need for a full night’s sleep
● Energy saving/lightweight/quiet
● Split structure, rooftop mounted
● Energy saving and low consumption, quality assurance
● The company has passed the automotive industry IATF16949 certification -
Olive Leaf Extract powder
Contact UsThe term “olive leaf” refers to a mixture of leaves and branches from both the pruning of olive trees and the harvesting and cleaning of olives. The production of olive leaves from pruning is ~25 kg p
-
Metal casings
Contact UsYancheng Zhongming New Materials Co., Ltd. is located in Yancheng City, Jiangsu Province.
-
PGA Frac Ball
Contact UsPGA fully degradable frac plug ball is a series of frac plug balls developed based on PGA degradable materials to meet the needs of oil fields under various temperatures and working conditions.
Reviews
There are no reviews yet.